Interleukin Genetics Reports First Quarter 2009 Financi...(31-Mar 31-Dec ...),Health

Date:5/14/2009

31-Mar 31-Dec 2009 2008 ---- ---- (Unaudited) (Audited) Cash and cash equivalents $1,746,523 $4,952,481 Total current assets 4,197,976 6,866,284 Total assets $9,575,198 $12,154,388 Total current liabilities $3,457,365 $3,666,961 Total liabilities 7,467,365 7,671,961 Total shareholders' equity 2,107,833 4,482,427 Total liabilities and shareholders' equity $9,575,198 $12,154,388 Three Months Ended Statement of Operations Data (Unaudited): March 31, 2009 2008 ---- ---- Revenue: Genetic testing service revenue $137,511 $101,752 Net consumer products sales 1,547,531 2,012,651 Contract research revenue 203,687 537,013 Other 6,266 3,107 ----- ----- Total revenue 1,894,995 2,654,523 --------- --------- Operating costs and expenses: Cost of genetic testing services 304,971 234,784 Cost of consumer products sold 737,728 1,101,188 Research and development 881,556 813,371 Selling, general and administrative 2,034,93
'/>"/>

SOURCE Interleukin Genetics, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
2. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
3. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
4. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
5. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
6. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
7. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
8. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
9. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
10. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
11. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results